Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.99 USD | +4.74% | -4.78% | -33.44% |
03-25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
03-25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Sales 2024 * | 265M 21.11B | Sales 2025 * | 406M 32.28B | Capitalization | 360M 28.64B |
---|---|---|---|---|---|
Net income 2024 * | -69M -5.49B | Net income 2025 * | 60M 4.78B | EV / Sales 2024 * | 1.36 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-4.71
x | P/E ratio 2025 * |
10.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +4.74% | ||
1 week | -4.78% | ||
Current month | -25.75% | ||
1 month | -28.67% | ||
3 months | -1.49% | ||
6 months | +140.83% | ||
Current year | -33.44% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 14/12/20 |
Director of Finance/CFO | 38 | 31/12/19 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 27/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 27/04/22 | |
J. Carroll
CHM | Chairman | 74 | 31/05/22 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 15/03/20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 237 M€ | +3.51% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.9 | -4.52% | 4,198,930 |
25/04/24 | 1.99 | -6.57% | 5,147,052 |
24/04/24 | 2.13 | +1.91% | 5,684,029 |
23/04/24 | 2.09 | +9.42% | 4,946,560 |
Delayed Quote Nasdaq, April 29, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.44% | 360M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- ESPR Stock